(NewsDirect)
Radiopharm Theranostics Ltd (ASX:RAD) CEO and managing directorRiccardo Canevari tells Proactive the company has begun the initiationprocess for entry into the Nasdaq stock exchange under the tickerRADX, gaining a second listing in the US capital market. RAD’srecently announced that it has received US FDA Investigational NewDrug Application (IND) approval for its ?V?6 Integrin (RAD301)technology. With this approval the company can start a Phase 1 imagingtrial in ambulatory patients with pancreatic cancer.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.